<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9959">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05686629</url>
  </required_header>
  <id_info>
    <org_study_id>ZGJAK-IIT-004</org_study_id>
    <nct_id>NCT05686629</nct_id>
  </id_info>
  <brief_title>An Efficacy and Safety Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia</brief_title>
  <official_title>A Study to Assess the Efficacy and Safety of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study adopts a randomized, double-blind, placebo parallel control design, and is&#xD;
      expected to include 120 eligible patients with severe novel coronavirus pneumonia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2023</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Jaktinib</measure>
    <time_frame>14 days after randomization</time_frame>
    <description>The proportion of subjects with disease progression or all-cause mortality;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of Jaktinib</measure>
    <time_frame>28 days after randomization</time_frame>
    <description>The proportion of subjects with disease progression or all-cause mortality;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of Jaktinib</measure>
    <time_frame>28 days after randomization</time_frame>
    <description>The proportion of subjects whose (National Institute of Allergy and Infectious Disease Ordinal Scale (NIAID-OS) score improved by â‰¥ 2 points from the baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of Jaktinib</measure>
    <time_frame>28 days after randomization</time_frame>
    <description>The change value of NIAID-OS score compared with the baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of Jaktinib</measure>
    <time_frame>up to 28 days after randomization</time_frame>
    <description>Time interval from randomization to clinical improvement (defined as NIAID-OS 1-3 points)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time interval from randomization to discharge</measure>
    <time_frame>up to 28 days after randomization</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of Jaktinib</measure>
    <time_frame>28 days after randomization</time_frame>
    <description>The proportion of subjects receiving mechanical ventilation due to disease progression at 3, 7, 14 days after randomization until end of treatment (EOT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of Jaktinib</measure>
    <time_frame>28 days after randomization</time_frame>
    <description>the proportion of subjects whose chest High-Resolution CT (HRCT) showed significant absorption of pulmonary inflammation (definition of significant absorption: the lung inflammatory lesions were reduced by more than 50%) at 7, 14 days after treatment until EOT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of Jaktinib</measure>
    <time_frame>up to 2 months after randomization</time_frame>
    <description>Incidence rate of adverse events and serious adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Novel COVID-19-Infected Pneumonia</condition>
  <arm_group>
    <arm_group_label>Jaktinib 100mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Jaktinib hydrochloride tablets, 2 x 50mg dosage, BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 x Placebo tablets, BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Jaktinib hydrochloride tablets</intervention_name>
    <description>2 doses per day, each containing two 50mg Jaktinib or placebo tablets</description>
    <arm_group_label>Jaktinib 100mg BID</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 to 80 years old (including threshold), regardless of gender;&#xD;
&#xD;
          -  There is a history of novel coronavirus antigen- or nucleic acid-positive infection&#xD;
             within 1 week;&#xD;
&#xD;
          -  HRCT is consistent with the manifestation of viral pneumonia (judged by the&#xD;
             investigator)&#xD;
&#xD;
          -  Participants who voluntarily sign informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants who cannot take orally, or are suspected to be allergic to Jaktinib&#xD;
             hydrochloride, similar drugs or their excipients, or have severe gastrointestinal&#xD;
             dysfunction that affects drug absorption;&#xD;
&#xD;
          -  Critical pneumonia patients with other organ failure requiring ICU monitoring and&#xD;
             treatment;&#xD;
&#xD;
          -  Participants who have received the following treatments within the specified time&#xD;
             window before randomization:&#xD;
&#xD;
               1. participants have received Janus kinase (JAK) inhibitor, interleukin 6 (IL-6)&#xD;
                  inhibitor, IL-1 inhibitor, tumor necrosis factor (TNF) inhibitor, T cell or B&#xD;
                  cell depletion agent, interferon and other immunosuppressive drugs within the&#xD;
                  first two weeks of randomization, except glucocorticoid;&#xD;
&#xD;
               2. Systematically used CYP 3A4 potent inhibitor or potent inducer in the first five&#xD;
                  drug half lives at random;&#xD;
&#xD;
          -  Immune deficiency;&#xD;
&#xD;
          -  Participants who have received novel coronavirus vaccine within 1 week before&#xD;
             randomization;&#xD;
&#xD;
          -  Prior to randomization, there were the following active and uncontrolled infections:&#xD;
             tuberculosis, HIV, syphilis, mycoplasma, chlamydia, parasites, and viral infections&#xD;
             other than SARS CoV-2 that required systemic anti-infection treatment;&#xD;
&#xD;
          -  Renal diseases requiring dialysis treatment;&#xD;
&#xD;
          -  Pregnant and lactating women;&#xD;
&#xD;
          -  Any other participants that were considered unsuitable by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weimin Li, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhu Luo</last_name>
    <phone>+86 18980606557</phone>
    <email>luozhu720@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>West China Hospital Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610042</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhu Luo</last_name>
      <phone>+86 18980606557</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>January 8, 2023</study_first_submitted>
  <study_first_submitted_qc>January 9, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2023</study_first_posted>
  <last_update_submitted>March 22, 2023</last_update_submitted>
  <last_update_submitted_qc>March 22, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

